| 2011
Alembic Pharmaceuticals Limited ( the Resulting C ompany ) was originally incorporated
on 16th June, 2010 in the name and style 'Alembic Pharma Limited', under the Companies
Act, 1956 and had received the Certificate of Commencement of business on 1st July, 2010.
The company changed its name from Alembic Pharma Limited to Alembic Pharmaceuticals
Limited and the Registrar of Companies, Gujarat has approved the change of name and
issued a fresh certificate of incorporation consequent upon change of name on 12th March,
2011.
2012
Alembic and Breckenridge Announce Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiqr).
Alembic Pharmaceuticals Limited enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA.
2013
-Alembic gets USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA.
2014
-"Alembic announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary - Alembic Global Holding S.A.".
2015
-Alembic Pharmaceuticals Ltd. arm signs exclusive agreement with Novartis
2016
- Alembic Pharma inks JV agreement with Orbicular Pharma
2017
-Alembic Pharmaceuticals partners with Breckenridge Pharma launching tablets used in the treatment of major depressive disorder.
-Alembic Pharma gets USFDA nod for generic antidepressant and anti-hypertension drugs.
-Alembic gets FDA tentative nod for erectile dysfunction drug.
-Alembic Pharma gets USFDA nod for anti-bacterial drug.
-Alembic Pharma completes acquisition of Orit Laboratories.
2018
-Alembic Pharma gets USFDA nod for ophthalmic solution.
-Alembic Pharma joint venture Aleor Dermaceuticals has received approval from the US health regulator for ointment which is used for temporary relief of pain.
-Alembic Pharmaceuticals has received approval from the US health regulator to market Desenlafaxine extended-release tablets, used to treat major depressive disorder.
-Alembic Pharma gets tentative USFDA nod for ophthalmic solution.
-Alembic bags approval for Bupropion Hydrochloride Tablets.
2019
-Alembic Pharma gets USFDA final nod for Travoprost Ophthalmic Solution.
-Alembic Pharma JV Aleor Dermaceuticals gets USFDA nod for plaque psoriasis treatment drug.
- Alembic Pharma gets USFDA nod for intraocular pressure reduction drug.
-Alembic Pharma gets USFDA nod for glaucoma treatment drug.
2020
-Alembic Pharma receives USFDA approval for Asenapine Sublingual Tablets.
-Alembic Pharma gets final USFDA nod for eye drops solution.
-Alembic Pharmaceuticals receives USFDA approval for ANDA Amantadine Hydrochloride Tablets.
-Alembic gets USFDA nod for Vilazodone Hydrochloride tablets used to treat depression.
-Alembic Pharma gets final USFDA nod for Fenofibrate tablets.
2021
-Alembic receives USFDA tentative approval for Selexipag Tablets.
-Alembic Pharmaceuticals receives USFDA tentative approval for Dabigatran Etexilate Capsules.
-Alembic Pharma gets USFDA nod for cancer treatment drug.
-Alembic Pharmaceuticals has subscribed to partnership interest in ABCD Technologies LLP.
2022
-Alembic Pharmaceuticals receives USFDA approval for Cyclophosphamide Capsules.
-Alembic Pharma gets USFDA nod for Entacapone tablets.
-Alembic Pharmaceuticals gets US FDA nod for antibiotic drug.
2023
-Alembic has a cumulative total of 182 ANDA approvals from USFDA.
2024
-Alembic Pharmaceuticals has received USFDA approval for generic Divalproex Sodium delayed-release capsules, used in the treatment of epilepsy.
-Alembic Pharmaceuticals has received USFDA approval for generic version of Paliperidone extended-release tablets indicated for the treatment of schizophrenia.
- Alembic Pharmaceuticals has received USFDA approval for the abbreviated new drug application (ANDA) for Ivosidenib tablets of strength 250 mg
|